Table 2 Comparing prescribing patterns before and after guideline convergence
From: Impact of recent guideline changes on aspirin prescribing after knee arthroplasty
Class of VTEP agent | Pre-period POD1 n (%) | Post-period POD1 n (%) | p value | Pre-period discharge n (%) | Post-period discharge n (%) | p value |
|---|---|---|---|---|---|---|
ASA monotherapya | 7 (4.64) | 79 (44.38) | <0.0001 | 21 (13.91) | 99 (55.62) | <0.0001 |
All other agents | 144 (95.36) | 99 (55.62) | 130 (86.09) | 79 (44.38) | ||
 LMWHb | 32 (21.19) | 10 (5.62) |  | 26 (17.22) | 13 (7.30) |  |
 Vitamin K antagonist | 57 (37.75) | 31 (17.42) | 64 (42.38) | 35 (19.66) | ||
 Xa inhibitorsc | 44 (29.14) | 36 (20.22) | 35 (23.18) | 20 (11.24) | ||
 Combinationd | 11 (7.28) | 20 (11.24) | 5 (3.31) | 11 (6.18) | ||
 LDUH 5000 U TID | 0 (0) | 2 (1.12) | 0 (0) | 0 (0) |